Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783223 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29833737 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19420453 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8049751 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3867845 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL562559 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5271544 | 1.00 | ANPEP (0.42) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5166344 | 0.94 | ANPEP (0.39) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6550318 | 0.83 | KDM1A (0.48) | ANPEPGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8077009 | 0.81 | ACHE (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068719-A1 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | VALDEZ JOHNNY | 2009-03-12 | — | — | US | disclosed |
| EP-1700122-A4 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | ARK DIAGNOSTICS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7202092-B2 | Indinavir derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1700122-A2 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | ARK DIAGNOSTICS (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20050244816-A1 | Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics | ARK DIAGNOSTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005062979-A2 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | ARK DIAGNOSTICS (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050148596-A1 | Indinavir derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6057479-A | MULTISTAGE REACTION OF HYDROXY INDANONE WITH AMINE TO FORM IMINE, HEATING AND HYDROGENATION | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0874059-A2 | PROCESSES FOR PRODUCING INDANE DERIVATIVES | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
| EP-0874059-A1 | PROCESSES FOR PRODUCING INDANE DERIVATIVES | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068719-A1 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | CD4, MPI, ME1 | ANPEP 65/4885GRIN2D 3962/4885GRIN3B 3587/4885 |
| US-20050148596-A1 | Indinavir derivatives useful in immunoassay | IMPDH1, DIMT1, INMT | ANPEP 461/4885GRIN2D 1947/4885GRIN3B 1517/4885 |
| US-20050244816-A1 | Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics | CD4, MPI, ME1 | ANPEP 65/4885GRIN2D 3962/4885GRIN3B 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.